undamentalytics Newsletter

Ideaya Biosciences, Inc. insider trading

Every open-market purchase and sale by Ideaya Biosciences, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Ideaya Biosciences, Inc. insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Ideaya Biosciences, Inc.’s insiders pay?

From June 22, 2020 to March 2, 2026, 5 insiders reported 3 open-market purchases and 2 sales not made under a pre-set plan in Ideaya Biosciences, Inc. Twelve months after each purchase was reported, the shares were +17.0% against the S&P 500 on average (median +17.0%), over 2 purchases with a full year of prices; 100% beat the index. After sales, the shares moved +4.9% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on June 23, 2020 into $17,505 by November 2, 2026, +9.2% a year. It held shares 27% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,759 (+10.4% a year), and held throughout $26,390 (+16.5%).

$0$10.0k$20.0k 2020202120222023202420252026 $26.4k$18.8k$17.5k
Copying Ideaya Biosciences, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Ideaya Biosciences, Inc.'s insiders from June 23, 2020, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 27% of the time.
Ideaya Biosciences, Inc.: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Bvf I Gp LLC 10% owner 1 +18.5% (1) 100% 0 — July 2, 2020
Bvf Partners L P/il Other 0 — — 1 −36.4% (1) February 4, 2021
Bvf Partners Os Ltd. 10% owner 1 +15.4% (1) 100% 0 — June 22, 2020
Schwab Andrew J. 10% owner 0 — — 1 +46.2% (1) November 13, 2020
Stein Jeffrey Director 1 — — 0 — March 2, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Ideaya Biosciences, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Ideaya Biosciences, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +27.3% against the index. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
July 31, 20202 buying−3.5%+27.3%+50.1%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Ideaya Biosciences, Inc. · Funds · Politicians